Expect to see growth from Novartis, Datamonitor says

NEW YORK Some of the strongest growth among large drug companies may come from Swiss drug maker Novartis, according to a new report by British market analysis firm Datamonitor.

Novartis is expected to deliver the strongest prescription pharmaceutical sales growth of any big pharma company in the 2009-2015 period, with a compound annual growth rate of more than 4%, compared with a compound annual growth rate of 1.4% for large drug companies overall. That would add more than $10 billion in sales, according to Datamonitor.

“Integral to Novartis delivering sales growth performance well above average is the company’s heavily diversified prescription pharmaceutical offering,” Datamonitor analyst Simon King said, citing Novartis generics arm Sandoz, currently the world’s second-largest maker of generic drugs, and its vaccines business.

Login or Register to post a comment.